Sequential Determination of Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid in Liver Transplant Patients Treated with Mycophenolate Mofetil
Authors:
- Mercé BrunetMBMercé Brunet
- Isabel CireraICIsabel Cirera
- Jaume MartorellJMJaume Martorell
- Elena VidalEVElena Vidal
- Olga MillánOMOlga Millán
- Olga JiménezOJOlga Jiménez
- Isabel RojoIRIsabel Rojo
- María-Carlota LondoñoMLMaría-Carlota Londoño
- Antoni RimolaARAntoni Rimola
- 1 February 2006
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Transplantation
- Vol. 81 (4) , 541-546
Abstract
In liver transplantation, mycophenolate mofetil (MMF) is habitually administered using fixed doses. We assessed whether mycophenolic acid (MPA) monitoring could be advisable in liver transplant patients. In 15 liver transplant patients receiving tacrolimus, daclizumab and MMF (1 g bid, orally), we determined the 12-hour plasma MPA pharmacokinetic profile after one dose of MMF at days 6, 10, and 16, and months 3 and 6. The inhibitory capacity of serum MPA on proliferation of CEM cells, a cell line insensitive to other immunosuppressants, was also determined. A large interindividual variability in MPA profiles was observed at any time. Regardless of a gradual increase in individual MPA AUC and C(0) over time following transplantation, a substantial proportion of patients had these parameters below the ranges recommended in other organ transplantations throughout the study. When MPA AUC and C(0) were within the recommended ranges, CEM proliferation was inhibited by almost all serum samples, but when these pharmacokinetic parameters were below the recommended ranges, CEM proliferation was very variable and, therefore, unpredictable. No relationship between MPA pharmacokinetics and the efficacy of MMF could be established (only one patient developed rejection), probably due to the concomitant administration of tacrolimus and daclizumab. Gastrointestinal symptoms were the only adverse events with a significant relationship with MPA levels. During the first postoperative months, exposure to MPA is low in a considerable proportion of liver transplant patients receiving MMF at a fixed dose of 1 g bid. MPA monitoring appears necessary in these patients.Keywords
This publication has 25 references indexed in Scilit:
- Intraindividual and Interindividual Variations in the Pharmacokinetics of Mycophenolic Acid in Liver Transplant PatientsThe Journal of Clinical Pharmacology, 2005
- Monitoring mycophenolate in liver transplant recipients: Toward a therapeutic rangeLiver Transplantation, 2004
- Mycophenolic Acid Pharmacodynamics and Pharmacokinetics Provide a Basis for Rational Monitoring StrategiesAmerican Journal of Transplantation, 2003
- Mycophenolic acid pharmacokinetics in pediatric liver transplant recipientsLiver Transplantation, 2003
- Current Issues in Therapeutic Drug Monitoring of Mycophenolic Acid: Report of a Roundtable DiscussionTherapeutic Drug Monitoring, 2001
- Pharmacokinetics of Mycophenolic Acid after Mycophenolate Mofetil Administration in Liver Transplant Patients Treated with TacrolimusThe Journal of Clinical Pharmacology, 2001
- Levels of mycophenolic acid and its glucuronide derivative in the plasma of liver, small bowel and kidney transplant patients receiving tacrolimus and cellcept combination therapyTransplant Immunology, 2000
- Mycophenolate mofetil and its mechanisms of actionImmunopharmacology, 2000
- Mycophenolate mofetilThe Lancet, 1996
- Mycophenolate MofetilDrugs, 1996